Skip to main content
Equibles
AQST logo

AQST · Aquestive Therapeutics, Inc.

Track AQST — free

Use AQST with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$5.29 -0.09 (-1.67%)
Russell 2000 member Rebalance outlook locked
Market Cap
$675.25M
Shares
125.51M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.38 Open$5.25 Day$5.25–5.39 52W close$2.95–7.49 Avg vol 30d3.3M Short int21.0M · 16.7% float · 5.2d Short vol48% Last earningsAug 12, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 8, 2026 Est · unconfirmed · in 9 wks
Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$54.09M
Trailing 12 months
Net income (TTM)
−$78.23M
Trailing 12 months
Revenue growth YoY
+38.1%
Year over year
Operating margin
-97.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.46M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+25.8%
Year over year · more shares
Price change (1Y)
+40.5%
Trailing year
Short interest
16.7%
Latest settlement · 5.2 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.2 · calm Equity put/call 0.56
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +20%
above
Price vs 50-day avg +26%
above
RSI (14) 71
overbought
MACD trend Positive
52-week position 54%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +43%
trailing
6-month return +34%
trailing
YTD return −17%
this year
Relative strength +19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.69% of float · ▲ +16.1% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
187 holders — near 3-yr high, broad support
Squeeze score 79
high risk · 0–100
Fundamentals
Weak
Revenue growth +1%
Y/Y
EPS growth −53%
Y/Y
Free cash flow $-53.0M
Balance sheet $83.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −61%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Prior guidance period ended · from the Earnings Call filed Dec 31, 2021
Non-GAAP adjusted gross margin · full year 2022 70% – 75%
Non-GAAP adjusted EBITDA loss · full year 2022 $51M – $58M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+20% Bullish
Price vs 50-day avg
+26% Bullish
RSI (14)
71 Bearish
MACD trend
Positive Bullish
52-week position
54% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.69% of float · ▲ +16.1% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
187 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $5 · 54% Range high $7
vs 200-day avg +20% vs 50-day avg +26%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AQST
Aquestive Therapeutics, Inc.
this stock
$675.25M -16.7% +0.8% — 16.7%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $66.37B — — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $58.66B +18.2% — — 0.1%
GALDY
Galderma Group AG/ADR
 $47.50B -1.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $43.03B +20.1% +4.3% 60.5 3.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
187
% held
58.8%
Net QoQ
+72.9K sh
Top holder
Bratton Capital Managemen…
Held Float
View
Held by Funds
Fund positions
114
View
Short & Settlement
Short Interest Rising
Shares short
21.0M
Days to cover
5.2d
Change
+2.9M sh
View
Short Volume
Short vol %
48%
As of
Sep 2, 2026
Short Total
View
Fails to Deliver
FTD shares
17.2K
Value
$73.1K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
43.0%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$44.5M
Net income (FY)
$-83.8M
EPS diluted
$-0.78
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
14
View
Proposed Sales
Value
$106.3K
Shares
25.0K
Filed
Aug 17, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
AQST -0.2% +43.3% +33.5% +5.3% -16.7%
SPY -0.1% -0.6% +14.9% -0.3% +12.2%
vs SPY -0.1% +43.9% +18.6% +5.5% -28.9%
Key facts CIK 1398733 CUSIP 03843E104 13F (30d) 153 filings 150 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)